Vor Bio Appoints Navid Khan as Chief Medical Affairs Officer.
PorAinvest
martes, 23 de septiembre de 2025, 8:10 am ET1 min de lectura
VOR--
Dr. Khan joins Vor Bio from argenx, where he served as Head of Neuromuscular Therapeutic Area, Medical Affairs, leading the integrated medical strategy and execution for four launches of VYVGART and VYVGART Hytrulo [1]. Prior to argenx, he held senior leadership positions at Akouos Inc. and Sarepta Therapeutics, where he played a pivotal role in the launch of three Duchenne muscular dystrophy therapies and prepared Sarepta’s Medical Affairs organization for gene therapy programs [1].
“Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio. “His deep scientific expertise, combined with his ability to connect with patients, physicians, and global stakeholders, will be invaluable as we advance telitacicept and shape our broader autoimmune portfolio” [1].
Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and his B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst [1]. He is excited about the opportunity to join Vor Bio at this critical juncture in its development and looks forward to contributing to the company’s mission of transforming the treatment of autoimmune diseases.
Vor Bio has appointed Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Khan has over two decades of experience in medical affairs, commercial, and R&D functions, overseeing 40 development programs and guiding seven product launches in neurology, immunology, and infectious diseases. He joins Vor Bio from argenx, where he led medical strategy and execution for four launches of VYVGART and VYVGART Hytrulo.
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, has appointed Dr. Navid Z. Khan, Ph.D., as its Chief Medical Affairs Officer [1]. Dr. Khan brings over two decades of experience in medical affairs, commercial operations, and R&D, with a proven track record of leading successful product launches in rare neurology and immunology indications.Dr. Khan joins Vor Bio from argenx, where he served as Head of Neuromuscular Therapeutic Area, Medical Affairs, leading the integrated medical strategy and execution for four launches of VYVGART and VYVGART Hytrulo [1]. Prior to argenx, he held senior leadership positions at Akouos Inc. and Sarepta Therapeutics, where he played a pivotal role in the launch of three Duchenne muscular dystrophy therapies and prepared Sarepta’s Medical Affairs organization for gene therapy programs [1].
“Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio. “His deep scientific expertise, combined with his ability to connect with patients, physicians, and global stakeholders, will be invaluable as we advance telitacicept and shape our broader autoimmune portfolio” [1].
Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and his B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst [1]. He is excited about the opportunity to join Vor Bio at this critical juncture in its development and looks forward to contributing to the company’s mission of transforming the treatment of autoimmune diseases.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios